Arrowhead Pharmaceuticals, Inc. (ARWR)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreNews headlines
Powered by Yahoo ScoutArrowhead Pharmaceuticals presented clinical data supporting durable triglyceride reductions and fewer acute pancreatitis events for plozasiran. The company also reported a lower-cost refinancing, while its ARO-DIMER-PA and ARO-MAPT programs broaden the pipeline across cardiovascular and neurological diseases.[1][2] ARWR rose 1.22% on November 6, including regular-session and after-hours trading; the market is closed, so this is not today's move.
No news stories available
